Reuters logo
BRIEF-Exelixis announces Independent Radiology Committee review confirms results from CABOSUN
June 19, 2017 / 12:21 PM / 5 months ago

BRIEF-Exelixis announces Independent Radiology Committee review confirms results from CABOSUN

June 19 (Reuters) - Exelixis Inc

* Exelixis announces independent radiology committee review confirms results from cabosun, the phase 2 trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

* Exelixis inc - u.s. Regulatory submission remains on track for q3‘17

* Exelixis - cabozantinib demonstrated clinically meaningful,statistically significant reduction in rate of disease progression or death as measured by pfs Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below